Pope Kendra V, Tun Alex E, McNeill Conor J, Brown Dorothy C, Krick Erika L
Department of Clinical StudiesSchool of Veterinary MedicineUniversity of PennsylvaniaPhiladelphiaPennsylvaniaUSA.
Hope Advanced Veterinary CenterViennaVirginiaUSA.
Vet Med Sci. 2015 Oct 29;1(2):51-62. doi: 10.1002/vms3.9. eCollection 2015 Oct.
Feline small cell lymphoma is associated with greater response to treatment and survival when compared to large cell lymphoma. Treatment-associated toxicity, response to rescue chemotherapy and prognostic factors are largely unknown. This retrospective study was performed to identify treatment-associated toxicity, response to rescue chemotherapy and treatment outcome for cats diagnosed with small cell lymphoma of various anatomic locations. Medical records from 56 cats were evaluated. All cats were treated with glucocorticoid and chlorambucil with discontinuation of treatment recommended at 1 year if complete clinical response was documented. Chemotherapy toxicity was uncommon (33.9%) and generally mild. Grade III or IV hepatotoxicity was documented in 10.7% of patients. Overall response rate was 85.7% with glucocorticoid and chlorambucil. Median progression-free survival was 1078 days. Overall response rate for rescue chemotherapy was 59%. Reintroduction of prednisone and chlorambucil was associated with significantly longer survival than prednisone and lomustine (>1500 vs. 492 days, = 0.01). Median overall survival times for cats with lymphoma of the gastrointestinal tract was not significantly different from those with extra-intestinal disease locations (1148 vs. 1375 days, = 0.23). Median overall survival was 1317 days. Toxicity, other than hepatotoxicity was mild. Rescue chemotherapy with re-introduction of glucocorticoids and chlorambucil was most successful. Discontinuation of glucocorticoid and chlorambucil with subsequent reintroduction as rescue chemotherapy appears to be just as effective as continued administration in cats.
与大细胞淋巴瘤相比,猫小细胞淋巴瘤对治疗的反应更好,生存期更长。治疗相关毒性、对挽救性化疗的反应以及预后因素在很大程度上尚不清楚。本回顾性研究旨在确定诊断为不同解剖部位小细胞淋巴瘤的猫的治疗相关毒性、对挽救性化疗的反应以及治疗结果。对56只猫的病历进行了评估。所有猫均接受糖皮质激素和苯丁酸氮芥治疗,若有完全临床缓解记录,则建议在1年后停止治疗。化疗毒性不常见(33.9%),且通常较轻。10.7%的患者记录有III级或IV级肝毒性。糖皮质激素和苯丁酸氮芥的总体缓解率为85.7%。无进展生存期的中位数为1078天。挽救性化疗的总体缓解率为59%。重新使用泼尼松和苯丁酸氮芥与泼尼松和洛莫司汀相比,生存期显著更长(>1500天对492天,P = 0.01)。胃肠道淋巴瘤猫的总生存期中位数与肠外疾病部位的猫无显著差异(1148天对1375天,P = 0.23)。总生存期中位数为1317天。除肝毒性外,毒性较轻。重新引入糖皮质激素和苯丁酸氮芥进行挽救性化疗最为成功。在猫中,停止使用糖皮质激素和苯丁酸氮芥,随后作为挽救性化疗重新引入似乎与持续给药同样有效。